Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 31HR+/HER2- Advanced Breast Cancer 3Breast Cancer Metastatic 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Esophageal Squamous Cell Carcinoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Breast Diseases 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1Advanced Breast Cancer 1

Interventions

Cisplatin 115Radiotherapy 83Paclitaxel 77Fluorouracil 61Carboplatin 41Drug Therapy 34pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26toripalimab 23Oxaliplatin 23Neoadjuvant Therapy 23Radiation 20sintilimab 19camrelizumab 19130-nm albumin-bound paclitaxel 18Esophagectomy 17Capecitabine 17Surgical Procedures, Operative 15Leucovorin 15Nivolumab 14Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10anlotinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Esophageal Squamous Cell Carcinoma × dalpiciclib × Clear all
NCT06684600 2024-11-12

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06225921 2024-03-06

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

West China Hospital

Phase 1 Unknown
6 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡